In addition to the already mentioned gene mutations, the TP53 mutation is found in approximately 8% of adult AML, is associated with older age, has complex and monosomal karyotypes, has a very poor outcome, and has been given a strong emphasis in recently proposed European LeukemiaNet (ELN) 2022 recommendations, but it is rarely seen in pediatric AML [41,42]. Here, TP53 is linked to acute myeloid leukemia.